Prime Medicine, Inc. 8-K

What Happened
Prime Medicine, Inc. (PRME) held its 2026 annual meeting of stockholders on June 5, 2026 (8-K filed June 8, 2026). Stockholders elected Michael Kelly and David Schenkein, M.D. as Class I directors (each to serve until the 2029 annual meeting) and ratified the appointment of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for fiscal 2026. Proxies were solicited under the proxy statement filed April 23, 2026.

Key Details

• Record date and participation: 180,615,889 shares outstanding as of April 9, 2026; 140,384,724 shares were present or represented by proxy at the meeting (quorum).
• Director votes: Michael Kelly — For 107,059,058; Withheld 3,047,945; Broker non-votes 30,277,721. David Schenkein — For 87,522,409; Withheld 22,584,594; Broker non-votes 30,277,721.
• Auditor ratification: PricewaterhouseCoopers LLP ratified as auditor for the year ending Dec. 31, 2026 — For 139,989,201; Against 101,259; Abstentions 294,264.

Why It Matters
Board elections determine company governance and oversight through 2029 for the two Class I seats; the voting tallies show differing levels of support for the nominees and a sizable block of broker non-votes present at the meeting. Ratification of PwC confirms the company’s auditor for fiscal 2026, providing continuity on audit and financial reporting matters. Investors monitoring governance, audit oversight, or potential strategic direction should note these outcomes and the disclosed voting breakdowns.